

Temporally Tunable, Enzymatically Responsive Delivery of Proangiogenic Peptides from Poly(ethylene glycol) Hydrogels

Amy H. Van Hove, Erin Antonienko, Kathleen Burke, Edward Brown III, and Danielle S. W. Benoit*

Proangiogenic drugs hold great potential to promote reperfusion of ischemic tissues and in tissue engineering applications, but efficacy is limited by poor targeting and short half-lives. Methods to control release duration or provide enzymatically responsive drug delivery have independently improved drug efficacy. However, no material has been developed to temporally control the rate of enzymatically responsive drug release. To address this void, hydrogels are developed to provide sustained, tunable release of Qk, a proangiogenic peptide mimic of vascular endothelial growth factor, via tissue-specific enzymatic activity. After confirmation that sustained delivery of Qk is necessary for proangiogenic effects, a variety of previously identified matrix metalloproteinase (MMP)-degradable linkers are used to tether Qk to hydrogels. Of these, three (IPES↓LRAG, GPQG↓IWGQ, and VPLS↓LYSG) show MMP-responsive peptide release. These linkers provide tunable Qk release kinetics, with rates ranging from 1.64 to $19.9 \times 10^{-3} \text{ h}^{-1}$ in vitro and 4.82 to $8.94 \times 10^{-3} \text{ h}^{-1}$ in vivo. While Qk is confirmed to be bioactive as released, hydrogels releasing Qk fail to induce significant vascularization in vivo after one week, likely due to the use of nonenzymatically degradable hydrogels. While Qk is the focus of this study, the approach could easily be adapted to control the delivery of a variety of therapeutic molecules.

Dr. A. H. Van Hove, E. Antonienko, Dr. K. Burke,
Prof. E. Brown III, Prof. D. S. W. Benoit
Department of Biomedical Engineering
207 Robert B. Goergen Hall
University of Rochester
Rochester, NY 14627, USA
E-mail: benoit@bme.rochester.edu

Prof. E. Brown III
Department of Neurobiology and Anatomy
University of Rochester
601 Elmwood Ave, Rochester, NY 14642, USA

Prof. D. S. W. Benoit
Department of Biomedical Genetics
601 Elmwood Ave
University of Rochester
Rochester, NY 14642, USA

Prof. D. S. W. Benoit
Department of Chemical Engineering
206 Gavett Hall
University of Rochester
Rochester, NY 14627, USA

Prof. D. S. W. Benoit
Center for Musculoskeletal Research
601 Elmwood Ave
University of Rochester Medical Center
Rochester, NY 14642, USA

DOI: 10.1002/adhm.201500304



1. Introduction

Proangiogenic therapies hold great potential for treatment of ischemic tissue disorders^[1] and in tissue engineering applications, where tissues larger than 100–200 μm in any dimension require supporting vasculature.^[2] Delivery of proangiogenic proteins^[3] and peptides^[4] has shown promising therapeutic results. Peptides offer advantages over proteins as they do not require complex tertiary structure for bioactivity, and due to small molecular weights, can be produced synthetically and delivered at higher concentrations to target tissues.^[4a] While peptides do not always fully recapitulate the bioactivity of the proteins they mimic, some, such as the vascular endothelial growth factor (VEGF) mimic Qk, show comparable bioactivity to protein counterparts.^[4] However, when simply injected in vivo, both proteins and peptides suffer from poor targeting and short half-lives due to rapid clearance and

degradation, necessitating the use of controlled release systems.^[5]

VEGF is one of the most common proangiogenic proteins exploited for therapeutic angiogenesis.^[3,6] However, tight spatio-temporal control over VEGF presentation is required to exploit its full potential and prevent the formation of immature, leaky vasculature.^[3,6e,7] Poly(lactic-co-glycolic acid)^[6c,d] and alginate^[3] materials have successfully extended the duration of encapsulated VEGF delivery through hindered diffusion or upon hydrolytic degradation, increasing tissue vascularization. However, these approaches deliver VEGF over predicted, and not necessarily therapeutically relevant, time frames. Alternately, enzymatically responsive hydrogels that release VEGF in response to local matrix metalloproteinase (MMP) expression have been developed.^[6a,b] These materials are based on the theory that microenvironmental concentrations of VEGF are critical for angiogenesis,^[6e] and cell-dictated release would result in ideal VEGF delivery profiles.^[6a,b] While the use of MMP-degradable tethers provides cell-dictated drug release, release rates were not manipulated due to use of a single, common MMP-cleavable substrate, precluding temporal control over enzymatically responsive VEGF delivery. Therefore, these previously developed materials are unable to investigate the role of temporally controlled enzymatically responsive growth factor delivery in angiogenesis.




Figure 1. Temporal control over enzymatically responsive peptide delivery. Eight-arm 20 kDa norbornene functionalized poly(ethylene glycol) (PEGN) is cross-linked with enzymatically stable peptide cross-linkers using a 2:3 thiol:ene molar ratio. The remaining norbornene groups are linked to the therapeutic peptide Qk via enzymatically degradable peptide tethers. By changing the enzymatically degradable tether and associated k_{cat}/K_M values, temporal control over enzymatically responsive peptide release was achieved. Not to scale.

In this work, the first materials approach to temporally control enzymatically responsive drug delivery was developed. Poly(ethylene glycol) (PEG)-based hydrogels were modified to provide enzymatically responsive release of the VEGF mimic Qk,^[4] a potent proangiogenic peptide that mimics the α -helix region of VEGF (Figure 1). Hydrogels were formed with Qk tethered to the gel via MMP-degradable peptide linkers (Table 1) utilizing five distinct linkers with a variety of reported k_{cat}/K_M values to temporally control release (Table S1, Supporting Information). The ability of Qk to retain bioactivity as released ("tail" form; Table 1) was assessed. Hydrogel swelling ratio, peptide incorporation efficiency, and enzymatically responsive peptide release behavior were also characterized. Hydrogels that demonstrated MMP-responsive release were implanted subcutaneously in vivo to track the in vivo release of fluorescently labeled peptides. Hydrogels vascularization in vivo was also assessed by measuring hemoglobin (Hb) content and imaged using multiphoton fluorescent microscopy.

2. Results and Discussion

2.1. Proangiogenic Potential of Qk

2.1.1. Qk Benefits from Sustained Release

The proangiogenic effect of Qk presented to cells transiently and continuously was first analyzed. A modified human umbilical vein endothelial cell (HUVEC) tube formation assay was developed that emulates bolus and sustained treatment (Figure 2A) with Qk or full-length VEGF. Bolus treatment (high dose for 5 min, followed by control media for 8 h) with VEGF did not induce significant tube networks (1.2-fold over control media); however, sustained treatment (low dose for 5 min, followed by low dose for 8 h) resulted in a significant 1.8-fold increase in tube length (Figure 2B). This is unsurprising, as activation of receptor tyrosine kinase signaling due to interactions of VEGF with VEGFR1 and VEGFR2 has been shown to be both time- and dose-dependent.^[7] Additionally, our assay results are consistent

Table 1. Peptide sequences utilized. Standard amino acid abbreviations are used. ↓ indicates MMP cleavage site. "Qk" is the VEGF peptide mimic KLTWQELYQLKYGI.^[4b] "Scrambled" is the scrambled control peptide GLKEQSPRKHRLG. While all linkers used here were reported in literature to be susceptible to cleavage by MMP2,^[8] the observed Qk release behaviors were not consistent with literature predictions. Therefore, peptide linkers are named based on their observed Qk release profiles as used in this application, and not based on their published linker-alone cleavage kinetics.

Type	Full name	Abbreviation	Sequence
"Linker" forms (for hydrogel tethering)	Qk with fast linker	Qk(FL)	"Qk"-PES↓LRAG-C-G (no extra C-terminal I)
	Qk with moderate linker	Qk(ML)	"Qk"-GPQG↓IWGQ-C-G
	Qk with slow linker	Qk(SL)	"Qk"-VPLS↓LYSG-C-G
	Qk with nonreleasing linker 1	Qk(NRL1)	"Qk"-SGESPAY↓YTA-C-G
	Qk with nonreleasing linker 2	Qk(NRL2)	"Qk"-PVS↓LRSG-C-G (no extra C-terminal I)
	Scrambled with fast linker	Scrambled(FL)	"Scrambled"-IPES↓LRAG-C-G
"Tail" forms (predicted release forms)	Qk with fast linker tail	Qk(FT)	"Qk"-PES-G (no extra C-terminal I)
	Qk with moderate linker tail	Qk(MT)	"Qk"-GPQG-G
	Qk with slow linker tail	Qk(ST)	"Qk"-VPLS-G
	Qk with nonreleasing linker 1 tail	Qk(NRT1)	"Qk"-SGESPAY-G
	Qk with nonreleasing linker 2 tail	Qk(NRT2)	"Qk"-PVS-G (no extra C-terminal I)
	Scrambled control peptide	Scrambled	"Scrambled" (no extra C-terminal G)
"Native" form (drug alone)	Native Qk	Qk(N)	"Qk"-G
	Scrambled control peptide	Scrambled	"Scrambled" (no extra C-terminal G)
Miscellaneous	Nonenzymatically degradable cross-linker	NDL	CLGKGKGLCG
	Cell adhesion peptide	RGD	CG-RGDS-G




Figure 2. In vitro analysis of the effect of bolus versus continuous delivery of Qk. A) Scheme of experimental setup, and B) results of tube formation data. A) To simulate bolus treatment, cells were pretreated with a high dose for 5 min then given control media alone for the remainder of the 8 h experiment. To simulate continuous delivery, cells received a low dose for the pretreatment phase as well as the remainder of the 8 h. Peptide doses were selected to have approximately the same dose duration ($0.01 \times 10^{-6} \text{ M} \times 8 \text{ h} \approx 1 \times 10^{-6} \text{ M} \times 5 \text{ min}$). VEGF doses were 10 ng mL^{-1} (bolus) and 1 ng mL^{-1} (continuous). &: $p < 0.01$, \$: $p < 0.001$ versus control media. $n = 9$, error bars represent SEM.

with in vivo data showing VEGF benefits from continuous, long-term delivery.^[3,6c,d] Similar to VEGF, only when continuously presented to cells did Qk significantly affect tube network formation (1.6-fold over control media). The control scrambled peptide did not significantly affect tube formation upon bolus or continuous treatment. To alleviate concerns about trypsin affecting the effects of the bolus treatment, a modified assay was performed when cells were treated in suspension with washes and media changes performed by centrifugation. VEGF and scrambled peptide showed similar trends regardless of trypsin use (Figure 2 and Figure S1, Supporting Information). Similar results between Qk and VEGF were expected, as Qk mimics the α -helix region of VEGF, and has been shown to bind both VEGFR1 and VEGFR2, resulting in similar levels of phosphorylation and ERK1/2 and Akt signaling.^[4a,c] Overall, these data suggest that the sustained availability of Qk is critical for its bioactivity, and sustained Qk release is likely to result in more robust proangiogenic effects. This is also consistent with previous in vivo reports, exploiting methods to provide sustained Qk delivery to ensure bioactivity, including osmotic pumps, Matrigel, and diffusive release from hydrogels.^[4a,b]

2.1.2. Qk Bioactivity Is Unaffected by Residual Amino Acids Present after MMP-Degradable Sequence Cleavage

MMP-degradable linkers described in literature and adapted for this work are cleaved in the middle of the sequence,

and therefore leave residual MMP substrates, or “tails,” on Qk when it is released (i.e., Qk “fast linker,” or Qk(FL) is KLTWQELYQLKYKGI-PES↓LRAG-C-G, and upon MMP cleavage releases Qk “fast linker tail,” or Qk(FT) KLTWQELYQLKYKGI-PES; Table 1). To determine if the residual peptide substrates affect bioactivity, Qk was tested in the HUVEC tube formation assay in both native “N” and as released “tail” forms (Figure 3). While the presence of some “tails” decreased the extent of tube formation induced by Qk (i.e., at $1 \times 10^{-6} \text{ M}$ Qk(NRT2) increased tube length ≈ 1.5 -fold, while Qk(N) increased tube formation ≈ 2.6 -fold control media), all “tail” forms of Qk significantly increased tube length over the same 100-fold concentration range as Qk(N). This confirms that Qk remains bioactive in its predicted released form for all five linkers, and all linkers warrant further investigation of temporally controlled enzymatically responsive Qk release.

2.2. Hydrogel Formation and Characterization

To facilitate hydrogel incorporation, Qk was synthesized in linker form, with an MMP-degradable linker and cysteine to allow for hydrogel incorporation on the C-terminus (Qk-linker-C-G; Table 1). Hydrogels were formed using a 2:3 cross-linking thiol:ene molar ratio, with the remaining 1:3 norbornene groups used for drug tethering (Figure 1).

2.2.1. All Linkers Resulted in Qk Hydrogel Incorporation and Altered Hydrogel Swelling Ratios

In comparison to fully cross-linked (1:1) hydrogels, the use of a 2:3 cross-linking thiol:ene molar ratio increased hydrogel swelling ratio from 19 to 28 mg mg^{-1} (Figure 4A). This is consistent with previous work showing swelling ratio increases as network cross-linking decreases.^[9] Interestingly, including tethered peptides reduced swelling ratio to levels similar to the fully cross-linked network, ranging from 18 to 21 mg mg^{-1} , but the swelling ratio was not affected by the specific peptide incorporated. This decrease in swelling ratio is likely due to intermolecular peptide interactions, similar to our previous observations.^[10] All peptide drug/linker combinations were successfully incorporated into hydrogels, with incorporation efficiencies varying from 75% and 69% for Qk(NRL2) and Scrambled(FL) to above 90% for Qk(FL), Qk(ML), Qk(SL), and Qk(NRL1) (Figure 4B).

2.2.2. Temporal Control over Enzymatically Responsive Peptide Release In Vitro Was Achieved

Hydrogels were formed with peptides tethered via MMP-responsive linkers and swollen overnight. Gels were incubated with $10 \times 10^{-9} \text{ M}$ MMP2, and peptide release was analyzed and compared with control gels incubated in buffer alone. Of the five linkers investigated, all which have been previously used as cross-links in enzymatically degradable PEG hydrogels,^[8] only three resulted in enzymatically responsive Qk release: FL, ML, and SL (Figure 5B–D). The other




Figure 3. In vitro screening of the impact of peptide linker "tail" on Qk bioactivity. A) Representative images of HUVEC tube formation at 0.1 μm, and B) fold increase in average tube length over within-plate control media. &: $p < 0.01$, \$: $p < 0.001$, #: $p < 0.0001$ versus control media. Scale bars = 250 μm, $n = 9$, error bars represent SEM.




Figure 4. Characterization of enzymatically responsive hydrogels in terms of: A) swelling ratio and B) % peptide incorporated. n.s.: $p > 0.05$, \$: $p < 0.001$, (a)–(d) indicate statistically equivalent groups. $n = 9$, error bars represent SEM.

two linkers, NRL1 and NRL2 did not result in detectable Qk release (Figure 5E,F). FL was also exploited to provide enzymatically responsive release of the negative control scrambled peptide (Figure 5A). As seen in Figure 5G, varying the enzymatically responsive linker used to tether Qk to the hydrogel successfully achieved temporal control over enzymatically responsive Qk release. Mass spectrometry on released peptides (Figure S2, Supporting Information) confirmed release in predicted "tail" forms used in bioactivity testing (Figure 3). Hydrogel mass over the time course of peptide release remained stable, confirming that peptide release was successfully uncoupled from hydrogel degradation (Figure S3, Supporting Information).

Interestingly, there was no clear relationship between reported k_{cat}/K_M values for the linker and release of Qk by that linker (Figure 5 and Table S1, Supporting Information). For example, NRL1 had the highest reported k_{cat}/K_M of any linker investigated but resulted in no detectable Qk release, while ML had the smallest k_{cat}/K_M investigated and resulted in moderate rates of enzymatically responsive Qk release. Changes in degradable linker peptide structure upon inclusion of the Qk peptide were examined using PEP-FOLD prediction software, shown to deviate from NMR structures by less than 3 Å.^[11] However, investigations into the length, number, and location of amorphous regions, α -helix, and β -sheets were uninformative in predicting release profiles (Figure S4, Supporting Information). Further investigation as to the role of linker size, hydrophobicity, and amino acid composition, as well as reported k_{cat} values for the linker and time to degradation of hydrogels formed using the peptide as a cross-linker^[8] were unable to satisfactorily predict Qk release rates (Figures S5 and S6, Supporting Information).

This makes design of similar systems challenging, as the literature values for sequence cleavage in solution cannot be used to predict linker release profiles. These results are not surprising, as linker sequence, MMP, linker-adjacent peptide modifications, and hydrogel incorporation have all been shown to affect cleavage kinetics.^[8,10,12] For example, the same modification to GPLGLWAQ increases its MMP3 cleavage rate threefold, but does not affect cleavage by MMP1.^[12] Modification of the linker IPES↓LRAG (FL) with different adjacent peptides affects MMP2 cleavage rate.^[10] Hydrogels cross-linked using MMP-responsive sequences SGESPAY↓YTA (NRL1) and GPQG↓IWGQ (ML) produce gels that degraded in ≈ 1 and ≈ 4 d in MMP2, while RPFS↓MIMG-cross-linked gels are stable for 10 d, despite contradictory reported k_{cat}/K_M values for MMP2 (440 000, 555, and 4600 $\text{M}^{-1} \text{s}^{-1}$ for NRL1, ML, and




Figure 5. Peptide release from enzymatically responsive hydrogels. Release of tethered peptide in the expected “tail” form from: A) Scrambled(FL), B) Qk(FL), C) Qk(ML), D) Qk(SL), E) Qk(NRL1), and F) Qk(NRL2) hydrogels, assessed using HPLC. G) All MMP-treated gels on the same plot, for comparison purposes (significances not indicated for clarity). *: $p < 0.05$, &: $p < 0.01$, #: $p < 0.0001$ versus buffer alone at same time point. $n = 6-12$, error bars represent SEM; some obscured by symbols.

RPFS↓MIMG, respectively).^[8] As additional materials are developed utilizing MMP-degradable sequences for controlled, enzymatically responsive drug release, the relationship between drug, degradable sequence, and linker cleavage kinetics will likely be further illuminated, facilitating predictive drug release profiles.

2.3. Temporal Control over Enzymatically Responsive Qk Release Was Achieved In Vivo but Did Not Affect Hydrogel Vascularization

Hydrogels were formed using fluorescently labeled peptides and implanted subcutaneously in mice after in vitro testing




Figure 6. Release of fluorescently labeled peptides in vivo, and comparison to in vitro release. A) Quantification of fluorescence over three weeks in vivo, normalized to average within-group day 0 fluorescence. Peptide release in vivo is significantly affected by both gel type and time ($p < 0.0001$), and there was a significant interaction between the factors ($p < 0.0001$). B) Pseudo-first order release coefficients (k_{rel}) were calculated for both in vitro and in vivo peptide release, to facilitate comparison of release kinetics. \$: $p < 0.001$, #: $p < 0.0001$. $n = 12$ for (A), 6–12 for (B); error bars represent SEM.

confirmed that live animal fluorescent imaging (IVIS) is an accurate and noninvasive method to track peptide release (Figure S7, Supporting Information). Subcutaneous implantation was selected as it is a commonly used method that allows for rapid assessment of vascularization (e.g., one week after implantation).^[13] Hydrogels were formed within nondegradable silicone reactors to aid in localization of the target tissue for collection and imaging (Figure S8, Supporting Information). Soluble controls were similarly injected into reactors after placement in the subcutaneous pocket. Specifically, hydrogels with fluorescently labeled Qk(FL), Qk(ML), Qk(SL), and Scrambled(FL) were studied.

2.3.1. Temporal Control over Enzymatically Responsive Peptide Release In Vivo Was Achieved

Upon subcutaneous implantation, temporal control over enzymatically responsive peptide released was demonstrated, with Scrambled(FL), Qk(FL), Qk(ML), and Qk(SL) releasing $\approx 50\%$ of the tethered peptide after $\approx 1, 3, 5$, and 7 d, respectively (Figure 6A). Peptide release was significantly affected by time and hydrogel type, with a significant interaction between the two factors ($p < 0.0001$). Undetectable amounts of peptide remained in gels after ≈ 1 – 2.5 weeks, depending on the linker utilized and the drug delivered. To facilitate quantitative comparisons of release profiles, in vitro and in vivo release data were fit to a pseudo-first order release model, and the release coefficients calculated (Figure 6B). In vitro, the release coefficient for Qk(FL) was the highest, followed by Scrambled(FL), Qk(ML), and Qk(SL) ($19.9, 12.1, 3.59$, and $1.64 \times 10^{-3} \text{ h}^{-1}$, respectively). In vivo, the release coefficient for Scrambled(FL) was the highest, followed by Qk(FL), Qk(ML), and Qk(SL) ($22.9, 8.9, 6.4$, and $4.8 \times 10^{-3} \text{ h}^{-1}$, respectively).

Interestingly, and despite releasing peptide with approximately the same profile in vitro (Figure 5G), the Scrambled(FL) hydrogels released peptide more quickly than Qk(FL) gels when implanted in vivo (Figure 6). This is likely due to

unexpected complete degradation of Scrambled(DL) gels. While all Qk-releasing gels were intact when collected for vascularization measurements at one week post-implantation, all Scrambled(FL) gels had degraded, contributing to the decrease in gel fluorescence observed and confounding the k_{rel} calculations. Due to the presence of the ester bond between the PEG and norbornene groups,^[9] all hydrogels used here are expected to be hydrolytically degradable over 1–2 months based on in vitro studies,^[9b] with PEG hydrogel degradation in vitro correlating well with in vivo behavior.^[14] However, exclusive degradation in vivo of the scrambled-peptide releasing gels was unexpected, as they were formed with the same enzymatically stable peptide cross-linker, had similar swelling ratios (Figure 4), and were stable over the same time frames in vitro as the Qk-releasing gels (Figure S3, Supporting

Information). While the cross-linking peptide was shown to be stable against MMP2 (Figure S3, Supporting Information), it is possible that nonspecific enzymatic degradation of the cross-linking peptide occurred. It is possible that degradation specifically of the Scrambled(FL) gels is due to inflammatory macrophage recruitment. The RGD peptide present in these hydrogels intended to facilitate vascular infiltration has also been shown to mediate macrophage adhesion and foreign body giant cell formation involved in the inflammatory response after implantation.^[15] Macrophages have been shown to degrade biomaterials by releasing hydrolytic enzymes, esterases, hydroxyl radicals, and many other reactive species that could contribute to accelerated cleavage of ester, ether, or amide bonds within hydrogel cross-links.^[16] Our results indicate delivery of the VEGF mimic Qk may have decreased the activity or number of macrophages present at the implant site, either by directly affecting macrophages or by initiating a feedback loop between tissue and immune cells.^[15] VEGF has been shown to shift macrophages from an inflammatory (M1) to a regenerative (M2) phenotype.^[17] As the VEGF mimic Qk shows similar receptor binding and biological effects to the full-length protein,^[4] it could be polarizing macrophages to an M2 rather than M1 phenotype, delaying macrophage-mediated degradation of Qk-releasing gels. However, additional investigations are necessary to support these theories.

All Qk-releasing gels remained stable in vitro and in vivo, allowing comparison of the release coefficients. Kinetics of drug release followed similar trends in vitro and in vivo, with Qk(FL) exhibiting the fastest release kinetics, followed by Qk(ML) and Qk(SL), although the k_{rel} values were not significantly different in vivo. Qk(ML) and Qk(SL) had statistically equivalent release rates in vitro and in vivo, but Qk(FL) released more rapidly in vitro. These results show that by altering the specific MMP-responsive linkage used to tether the drug to the hydrogel, cell-dictated peptide release can be temporally manipulated. This provided a method for exquisite control over the in vitro and in vivo presentation of Qk to target cells/tissues. While the relative release rates were consistent between in vitro and in vivo




Figure 7. Enzymatically responsive Qk-releasing hydrogels were formed in nondegradable reactors and implanted subcutaneously in mice. One week after implantation, vascularization into the reactor was assessed via A) hemoglobin content and B,C) by multiphoton fluorescent imaging. B) Representative images of collagen (SHG, blue) and vasculature (FITC-dextran, red) formed within reactors. C) Quantification of average vessel diameter. n.s.: $p > 0.05$, *: $p < 0.05$, \$: $p < 0.001$. $n = 14$ – 16 for (A), 6 – 8 for (C); error bars represent SEM. Scale bar = $100\ \mu\text{m}$.

conditions, the relative differences in release were not. There was a 12-fold difference in k_{rel} between Qk(FL) and Qk(SL) in vitro, but only a 1.9-fold difference in vivo. This provides useful information for design of similar systems; differences in release profiles are dampened when exposed to the more complex in vivo environment. Based on these results, degradable linkers should be selected that provide ≈ 5 – 10 -fold larger differences in release rates in vitro than are desired for in vivo release (i.e., if a threefold difference in release rate is desired in vivo, linkers should be identified that produce 15–30-fold differences in in vitro rates).

Differences in release rates between in vitro and in vivo conditions were not unexpected, and are consistent with other studies.^[6a] Numerous MMPs are expressed in vivo, with differential expression profiles based on the tissue and extent of injury or disease state.^[18] Additionally, tissue inhibitors of metalloproteinases (TIMPs) present in vivo could affect MMP activation levels.^[18b] As the linkers investigated here are reported to be susceptible to multiple MMPs (Table S1, Supporting Information), it is possible that MMPs other than the MMP2 used in vitro are contributing to peptide release in vivo. Due to differential MMP expression that occurs based on tissue type and injury,^[18] it is likely that the release profiles achieved in this study would not directly correlate with release in a different tissue (i.e., ischemic hind limb or cardiac tissue). However, the material developed here would likely still provide differential enzymatically responsive release profiles, and alternate MMP-degradable linkages^[8,19] could be investigated if the desired temporal release profiles were not achieved.

2.3.2. Nonenzymatically Degradable Qk-Releasing Hydrogels Do Not Induce Vascularization after One Week

While the main goal of this work was to develop a method to temporally control enzymatically responsive peptide delivery, a secondary goal was to study the effects of temporal control over enzymatically responsive Qk release on angiogenesis in

vivo. Therefore, vascularization resulting from Qk-releasing hydrogels was assessed. One week after implantation, hydrogel-containing reactors were explanted and vascular ingrowth was quantified by measuring Hb. Multiphoton fluorescent microscopy was also used to qualitatively assess vasculature. Neither the Qk-releasing hydrogels nor soluble Qk significantly affected Hb relative to phosphate buffered saline (PBS) or scrambled-peptide releasing (Figure 7A). Similarly, while variations in average vessel size between treatment groups were observed (from 15 to 22 μm for Qk(SL) and Qk(N), respectively), there was no significant difference between treatment groups (Figure 7C). However, preliminary studies examining vascularization of hydrogels four weeks after implantation shows significantly greater Hb resulting from Qk(ML) and Qk(SL) versus Qk(FL) gels (Figure S9, Supporting Information), suggesting the therapeutic potential of these hydrogels and the influence of temporally controlled enzymatically responsive peptide release.

While it did not significantly induce vascularization as a soluble, injected drug here, Qk(N) has been shown to be proangiogenic in vivo when delivered using alternate approaches. For example, when Qk is encapsulated within Matrigel and implanted subcutaneously, vascularization is significantly increased compared to controls.^[4b] Matrigel provides a degree of sustained delivery and a physical matrix facilitating cellular adhesion and infiltration not provided by the soluble injection control here.^[20] This is likely the reason the Qk(N) peptide did not induce a significant angiogenic response in this study. Lackluster vascularization one week after implanting hydrogels providing enzymatically responsive Qk release was observed. One week is a commonly used assessment point for vascularization of subcutaneous implants,^[13] and the positive control VEGF significantly increased vascularization, supporting the validity of the in vivo model. The temporal release profiles obtained here (≈ 1 – 2.5 weeks in vivo) are likely not the cause for the lackluster vascularization, as they are within the range of release profile ranges previously shown to improved vascularization via VEGF delivery (≈ 2 – 3 weeks).^[3a,6a,d] However, some materials have

shown improved vascularization when release occurred over ≈ 3 –4 weeks,^[21] suggesting it could be advantageous to identify MMP-degradable tethers that further prolongs Qk delivery. It is possible that released Qk lacks bioactivity. However, this is unlikely, as Qk was confirmed to be bioactive in the form it is released from the gels (Figure 3 and Figure S2, Supporting Information). It is more likely that minimal vascularization observed with Qk-releasing hydrogels is due to the nonenzymatically degradable nature of the hydrogels employed. In this initial study, hydrogels were designed to be stable over the time course investigated, to prevent confounding Qk release with hydrogel degradation (as was observed with the Scrambled(FL) gels). However, this causes hydrogels to present physical resistance to infiltrating vasculature due to the small mesh sizes of the gels (≈ 16 –17 nm),^[9b] regardless of the proangiogenic signals delivered. It is possible that released peptides diffused into nearby tissue and induced vascularization near the hydrogel implant. However, vasculature in nearby tissue was not assessed due to difficulty discriminating between pre-existing host vasculature and vasculature that developed in response to hydrogels. Preliminary studies looking at vascularization of these hydrogel after four weeks, e.g., once gels were degraded, showed greater vascularization than at the one-week time point used here (Figure 7 and Figure S9, Supporting Information), further supporting these conclusions. Use of degradable hydrogels either via enzymatic or temporally relevant hydrolytic mechanisms has been shown to greatly improve cell invasion in vitro^[8] and in vivo.^[6a] Future studies could employ an enzymatically degradable cross-linking peptide for hydrogel formation,^[8,22] facilitating simultaneous cell-dictated hydrogel degradation and drug release, likely increasing the proangiogenic efficacy of the hydrogels.

While this material was designed to achieve temporal control over enzymatically responsive release of Qk, the hydrogel system could be easily translated to deliver any number of therapeutic peptides with a range of functionality (e.g., proangiogenic,^[23] anti-inflammatory,^[24] or chemotherapeutic).^[25] The material could also be used for controlled delivery of protein drugs, with the inclusion of degradable linkages at either the C- or N-termini. It could also be used to deliver nonpeptide therapeutics that contain complementary chemical functionalities to allow for tethering to MMP-degradable linkers.^[26] However, as linker-adjacent modification has been shown to affect cleavage kinetics, delivery of different therapeutic agents would likely require different MMP-degradable linkers to achieve similar temporal release profiles.^[10,12] It is possible that inclusion of a spacer such as linear PEG or poly(glycine) between the MMP-degradable linkage and the therapeutic sequence could decrease the influence of the therapeutic on linker cleavage kinetics (e.g., by reducing steric hindrance),^[27] and result in drug release profiles that more closely emulate well-established soluble linker cleavage kinetics.

3. Conclusions

In conclusion, we developed a PEG hydrogel system providing temporally controlled enzymatically responsive release of the proangiogenic peptide Qk, for which sustained release was

confirmed necessary for bioactivity. Qk was successfully incorporated into PEG hydrogels using five MMP-degradable linkers. Three of the linkers (IPES↓LRAG (FL), GPQG↓IWGQ (ML), and VPLS↓LYSG (SL)) provided a range of MMP-responsive peptide release rates both in vitro and in vivo. While unable to promote significant vascularization in vivo one week after implantation, likely due to the slow degradation of the hydrogels, temporally controlled enzymatically responsive peptide release was attained. This approach can be readily adapted for controlled delivery of a number of therapeutic peptides, proteins, and small molecule drugs, and provides a means to study how temporal control over cell-dictated release affects drug efficacy.

4. Experimental Section

Materials and Methods: Unless otherwise noted, all chemicals were obtained from Sigma-Aldrich, all amino acids from AAPPTec, and all cell culture materials from Lonza.

Peptide Synthesis: Peptides were synthesized as previously described (Table 1).^[10] O-benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluorophosphate (0.5 M, AnaSpec) in dimethylformamide (DMF) and diisopropylethylamine (2 M, DIEA, Alfa Aesar) in *N*-methylpyrrolidone was used as the activator and activator base for RGD, NDL, and "N" and "T" peptides, and diisopropylcarbodiimide (0.5 M, Chem-Impex International) and hydroxybenzotriazole (1 M, Advanced ChemTech) in DMF as activator and activator base for all "L" peptides. Peptides were cleaved in trifluoroacetic acid (TFA, Alfa Aesar) containing 3,6-dioxo-1,8-octanedithiol (Alfa Aesar), triisopropylsilane (Alfa Aesar), and distilled, deionized water (ddH₂O) (2.5 vol% each), with thioanisole (2.5 vol%, Alfa Aesar) if the sequence included arginine. After 3–6 h, peptides were precipitated and washed in ether.

Peptide Purification and Assessment: Synthesis was confirmed using matrix-assisted laser desorption ionization time of flight (MALDI-ToF) mass spectrometry (Bruker). Peptides were dialyzed in ddH₂O overnight using 1–500 or 1000 MWCO tubing (Spectrum Laboratories). After collection by lyophilization, percent peptide was determined by measuring absorbance at 205 nm (Evolution 300 UV-vis detector, Thermo Scientific).^[28] Peptide purity was determined to be $\approx 90\%$ as measured by high-performance liquid chromatography (HPLC, Shimadzu Prominence) on a Kromasil Eternity C18 column (4.6 $\times$ 50 mm) running a gradient from 5% to 95% acetonitrile in water (both containing 1% TFA).

Fluorescent Peptide Labeling: Qk(FL), Qk(ML), Qk(SL), and Scrambled(FL) were selectively labeled at the N-terminal primary amine by reacting on-resin peptides with Texas Red succinimidyl ester (Life Technologies). Texas Red in DMF (2 mg, 10 mg mL⁻¹) was added dropwise to peptide in DMF (0.25 $\times$ 10⁻³ M in 3 mL) containing three drops DIEA. The mixture was protected from light and stirred overnight at room temperature. The peptide was cleaved and precipitated as above. The labeled peptide was purified by dialysis in ddH₂O until the water remained clear for at least 6 h, and labeled peptide collected by lyophilization.

HUVEC Cell Culture: HUVECs, originally from Lonza, were a gift from Dr. Stephen Dewhurst. After thawing from cryostorage, cells were maintained in endothelial growth media-2 (endothelial basal media-2 (EBM-2) containing EGM-2 SingleQuots; EGM-2), at 37 °C with 5% CO₂. Cells were used at least two passages after thawing, but prior to passage 10. Control media consisted of EBM-2 containing fetal bovine serum (2.5 vol%, Atlanta Biologicals), penicillin (100 U mL⁻¹), streptomycin (100 U mL⁻¹), and amphotericin B (250 ng mL⁻¹, Thermo Scientific).

HUVEC Tube Formation Assay: Tube formation was assessed as previously described,^[10] with minor modifications to simulate bolus versus continuous treatment. HUVECs were grown to 60%–70% confluency, then washed and treated for 5 min. Cells were then washed,

trypsinized, resuspended in the continuous treatment, and seeded on Matrigel (2.4×10^4 cells/well; Figure 2A). For the dose response testing, HUVECs were suspended directly in the treatment solution and seeded on Matrigel, with no pretreatment step. All cells were fluorescently imaged ($0.5 \mu\text{L mL}^{-1}$ calcein AM, Invitrogen) 8 h after seeding on Matrigel, using a Nikon Eclipse Ti 2000 inverted light microscope with temperature/humidity control (Pathology Devices).^[29] Tube length was quantified using the image processing program Angioquant.^[30]

Poly(ethylene glycol) Norbornene Synthesis: PEGN was synthesized from eight-arm 20 kDa PEG (JenKem Technologies, USA) as previously described.^[31] Functionalization was determined to be >95% by $^1\text{H-NMR}$ (400 MHz, CDCl_3 , δ): 6.25–5.8 (m, 8H, norbornene vinyl protons), 4.35–4.05 (d, 8H, $-\text{COOCH}_2$), 3.9–3.35 (m, 892H, $-\text{CH}_2\text{CH}_2\text{O}-$). The final product was dialyzed overnight in ddH_2O using 1000 MWCO dialysis tubing, collected by lyophilization, and stored at -20°C .

Hydrogel Formation: Hydrogels were formed as previously described,^[10] with minor modifications. All gels contained 10 wt% PEGN with a 2:3 cross-linking thiol:ene ratio using NDl as the cross-linking peptide, with the remaining 1:3 thiol:ene containing tethered drug, unless otherwise specified. Lithium phenyl-2,4,6-trimethylbenzoylphosphine (0.05 wt%, LAP, synthesized as described^[32]) was used as photoinitiator, and acetonitrile/water (25/75 vol/vol) used as the solvent to improve Qk solubility.^[10] 40 μL of hydrogel precursor solution was injected into a custom cylindrical Teflon mold (≈ 5 mm in diameter, ≈ 2 mm in height) and exposed to 10 min 365 nm UV light ($\approx 2.5 \text{ mW cm}^{-2}$) to induce polymerization. All hydrogels were swollen overnight in buffer ($10 \times 10^{-3} \text{ M CaCl}_2$, $50 \times 10^{-3} \text{ M NaCl}$, $50 \times 10^{-6} \text{ M ZnCl}_2$ (Alfa Aesar), $50 \times 10^{-3} \text{ M Tricine}$ (Acros Organics), and 0.05 wt% Brij35 (Alfa Aesar) in ddH_2O , pH 7.4) at 37°C prior to use. For in vivo studies, gels also contained $2.8 \times 10^{-3} \text{ M RGD}$ to facilitate cell adhesion, and fluorescently labeled peptides were used to facilitate tracking. Gels were polymerized within reactors (OD = 7.94 mm, ID = 4.76 mm, $h = 2.25$ mm) cut from pharmaceutical grade silicone tubing (Thermo Scientific), to facilitate tissue identification for collection. These reactors are similar to the Angioreactors used in the directed in vivo angiogenesis assay (DIVAA) which have been shown to induce only mild inflammatory infiltration.^[33] However, the increased exposed surface area of the reactors used in this study allows for a more accurate simulation of reactor-free implantation. Reactors were placed in a custom Teflon holder temporarily capping the bottom end. Precursor solution (40 μL) was then pipetted into the reactor and gels were polymerized in situ. Gels in reactors were then transferred to a 24-well plate, where they were incubated in buffer overnight before subcutaneous implantation (Figure S8, Supporting Information).

Hydrogel Characterization: Hydrogel swelling ratio was determined by measuring gel mass prior to and after lyophilization ($Q = M_{\text{wet}}/M_{\text{dry}}$; mg mg^{-1}). Peptide incorporation efficiency was assessed by forming gels with known amounts of drug in the precursor solution, incubating gels overnight in buffer, collecting buffer, and assessing the amount of peptide released using HPLC as described for peptide purification. Peak areas (absorbance at 214 nm for Scrambled peptides and 278 nm for Qk peptides) were compared to a standard curve to determine the amount of peptide released into buffer. The incorporation efficiency was then back-calculated based on the amount used to form the gel and the amount of peptide released (not incorporated into the gel) (%drug incorporated = $(M_{\text{precursor solution}} - M_{\text{released in buffer}})/M_{\text{precursor solution}} \times 100\%$).

Characterizing Peptide Release: After overnight swelling, gels were transferred to fresh buffer or buffer with $10 \times 10^{-9} \text{ M}$ recombinant human MMP2 (PeproTech). Solutions were collected and replaced periodically, at a minimum once every 48 h as MMP2 inactivates fairly rapidly.^[8] Solutions were stored at -20°C until peptide release was quantified using HPLC, as before. Peptide release data were fit to a pseudo-first order release equation

$$\frac{D_t}{D_0} \propto e^{-k_{\text{rel}} \times t} \quad (1)$$

where D_t is the drug remaining in the gel at time t , D_0 is the initial drug loaded in the gel, and k_{rel} is the pseudo-first order release rate.^[34]

In Vivo Testing: All animal procedures were approved by the University Committee of Animal Resources (UCAR) at the University of Rochester. 6–8 week old female BALB/c mice (Taconic) were used for all studies. Buprenorphine (3.25 mg kg^{-1}) was given immediately prior to surgery and every 12 h thereafter as necessary for pain. Mice were randomly assigned to treatment groups, making sure each treatment group spanned at least two surgery days.

Subcutaneous Implantation Model: Mice were anesthetized (60 mg kg^{-1} ketamine, 4 mg kg^{-1} xylazine). Fur was removed using clippers followed by Nair. A subcutaneous pocket was formed on each side of the mouse dorsal flank, and a hydrogel within a reactor (formed as described above) placed in each pocket. For soluble treatment (PBS, $11.7 \times 10^{-3} \text{ M Qk(N)}$, and $80 \mu\text{g mL}^{-1}$ VEGF), empty reactors were placed in the pocket and 40 μL of solution injected into the reactor in situ. Incisions were closed with skin glue.

Peptide Release Tracking: Peptide release was tracked using the IVIS live animal imaging system as previously described,^[14] using $\lambda_{\text{ex/em}} = 570/620 \text{ nm}$ (Xenogen IVIS-200 Optical In Vivo Imaging System, Caliper Life Sciences Inc.). Mice were imaged immediately following surgery and isoflurane inhalation used as anesthesia for subsequent imaging sessions. Mice were re-depilated as necessary to reduce background signal from fur. Fluorescence (total radiant efficiency, $[(\text{p s}^{-1}) (\mu\text{W cm}^{-2})^{-1}]$) was measured using a ROI of constant area, and normalized by within group average day 0 fluorescence. Release data were fit to a pseudo-first order model, using a modified version of Equation (1) where F_t/F_0 (gel fluorescence at time t over initial gel fluorescence) was used in place of D_t/D_0 .

Quantification of Vascular Ingrowth: 7 d after implantation, vascular ingrowth was assessed by measuring hemoglobin within the reactor, shown to correlate well with other measures of angiogenesis.^[35] Reactors were explanted, and residual hydrogel and ingrown material removed and placed in 1 mL Drabkin's reagent (RICA Chemical). Samples were homogenized via sonication, centrifuged for 20 min at 14 000 g, and then filtered through $0.45 \mu\text{m}$ polyvinylidene (PVDF) filters (PerkinElmer). Absorbance at 540 nm was determined relative to the reference wavelength of 650 nm, and a hemoglobin standard curve used to determine the hemoglobin concentration.^[35c]

Multiphoton Imaging: Mice were anesthetized by ketamine/xylazine injection, and 2 mM M_w fluorescein isothiocyanate (FITC)-dextran (10 mg mL^{-1} , FITC, Life Technologies) in PBS (50 μL) injected retro-orbitally. After 1 h, mice were sacrificed and the dorsal flank opened to expose the hydrogel reactor for in situ imaging. Excitation light generated using a MaiTai Ti:Sapphire laser was directed toward the sample through a BX61WI upright microscope (Olympus). An Olympus Fluoview FV300 scanning system further controlled beam scanning and image acquisition. 350 mW of 810 nm light, with 100 fs pulses at 80 MHz was directed into the scan box to image all samples. Excitation light was focused and the backscattered fluorescent and second harmonic generation (SHG, collagen) signal was collected using an Olympus UMLFL20XW water immersion lens (20 $\times$, 0.95 NA). Signals were separated from the excitation beam first using a 670 nm short pass dichroic mirror, and then separated from each other using a 475 nm long pass filter. 535 nm band-pass (HQ535/40m-2P, Chroma) and 405 nm band-pass filters (HQ405/30m-2P, Chroma) were used to filter the FITC and SHG emission signals, respectively, with Hamamatsu HC125-02 photomultiplier tubes used to collect both channels. Images were collected from the same five locations in each reactor. 21 images taken every 5 μm were taken at each location and then maximum intensity projected to form a 100 μm stack. Vessel diameter was measured manually in ImageJ, with five of the largest vessels in each image quantified, and the average diameter for the gel reported. Images were collected and vessel measurements made by a user blinded to treatment groups.

Statistical Analysis: Data assembly and calculations were performed using Microsoft Excel (2010 v14.0). Figure preparation and statistical analysis were performed using Graphpad Prism (5.04). All data are shown as mean $\pm$ standard error of the mean (SEM). Data presented in Figures 2, 5, and 6 were analyzed using a two-way ANOVA; data

in Figures 3, 4, and 7 were analyzed using a one-way ANOVA, with post hoc testing (Bonferroni, Tukey, or Dunn) as necessary. All experiments were performed in at least duplicate to reach $n = 6-16$ as indicated in legends. $p < \alpha = 0.05$ was considered significant for all analyses.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

The authors would like to thank the Howard Hughes Medical Institute Med-into-Grad fellowship (A.H.V.H.), the National Institute of Health (R01 AR064200 (D.S.W.B.), F31CA183351 (K.B.), and T32AI007285 (K.B.)), and the Department of Defense (W81XWH-09-1-0405 (E.B.)) for funding. The authors would also like to thank Dr. Alex Shestopalov and Dr. James McGrath for the use of their equipment, and Dr. Stephen Dewhurst for providing HUVECs.

Received: April 24, 2015

Revised: June 10, 2015

Published online: July 7, 2015

- [1] I. Zachary, R. D. Morgan, *Heart* **2011**, 97, 181.
- [2] M. Lovett, K. Lee, A. Edwards, D. L. Kaplan, *Tissue Eng., Part B* **2009**, 15, 353.
- [3] a) E. A. Silva, D. J. Mooney, *Biomaterials* **2010**, 31, 1235; b) E. A. Silva, D. J. Mooney, *J. Thromb. Haemostasis* **2007**, 5, 590.
- [4] a) F. Finetti, A. Basile, D. Capasso, S. Di Gaetano, R. Di Stasi, M. Pascale, C. M. Turco, M. Ziche, L. Morbidelli, L. D. D'Andrea, *Biochem. Pharmacol.* **2012**, 84, 303; b) G. Santulli, M. Ciccirelli, G. Palumbo, A. Campanile, G. Galasso, B. Ziaco, G. G. Altobelli, V. Cimini, F. Piscione, L. D. D'Andrea, C. Pedone, B. Trimarco, G. Iaccarino, *J. Transl. Med.* **2009**, 7, 41; c) L. D. D'Andrea, G. Iaccarino, R. Fattorusso, D. Sorriento, C. Carannante, D. Capasso, B. Trimarco, C. Pedone, *Proc. Natl. Acad. Sci. U.S.A.* **2005**, 102, 14215.
- [5] a) D. J. Craik, D. P. Fairlie, S. Liras, D. Price, *Chem. Biol. Drug Des.* **2013**, 81, 136; b) R. J. Laham, M. Rezaee, M. Post, F. W. Sellke, R. A. Braeckman, D. Hung, M. Simons, *Drug Metab. Dispos.* **1999**, 27, 821.
- [6] a) E. A. Phelps, N. Landazuri, P. M. Thule, W. R. Taylor, A. J. Garcia, *Proc. Natl. Acad. Sci. U.S.A.* **2010**, 107, 3323; b) A. H. Zisch, M. P. Lutolf, M. Ehrbar, G. P. Raebler, S. C. Rizzi, N. Davies, H. Schmokel, D. Bezuidenhout, V. Djonov, P. Zilla, J. A. Hubbell, *FASEB J.* **2003**, 17, 2260; c) F. R. Formiga, B. Pelacho, E. Garbayo, G. Abizanda, J. J. Gavira, T. Simon-Yarza, M. Mazo, E. Tamayo, C. Jauquicoa, C. Ortiz-de-Solorzano, F. Prosper, M. J. Blanco-Prieto, *J. Controlled Release* **2010**, 147, 30; d) Q. H. Sun, R. R. Chen, Y. C. Shen, D. J. Mooney, S. Rajagopalan, P. M. Grossman, *Pharm. Res.* **2005**, 22, 1110; e) C. R. Ozawa, A. Banfi, N. L. Glazer, G. Thurston, M. L. Springer, P. E. Kraft, D. M. McDonald, H. M. Blau, *J. Clin. Invest.* **2004**, 113, 516.
- [7] a) K. Gupta, S. Kshirsagar, W. Li, L. Z. Gui, S. Ramakrishnan, P. Gupta, P. Y. Law, R. P. Hebbel, *Exp. Cell Res.* **1999**, 247, 495; b) C. J. Marshall, *Cell* **1995**, 80, 179; c) W. H. Zhu, A. MacIntyre, R. F. Nicosia, *Am. J. Pathol.* **2002**, 161, 823.
- [8] J. Patterson, J. A. Hubbell, *Biomaterials* **2010**, 31, 7836.
- [9] a) J. J. Roberts, S. J. Bryant, *Biomaterials* **2013**, 34, 9969; b) H. Shih, C. C. Lin, *Biomacromolecules* **2012**, 13, 2003.
- [10] A. H. Van Hove, M. J. Beltejar, D. S. Benoit, *Biomaterials* **2014**, 35, 9719.
- [11] P. Thevenet, Y. M. Shen, J. Maupetit, F. Guyon, P. Derreumaux, P. Tuffery, *Nucl. Acids Res.* **2012**, 40, W288.
- [12] S. Vessillier, G. Adams, Y. Chernajovsky, *Protein Eng., Des. Sel.* **2004**, 17, 829.
- [13] a) Y. Tabata, M. Miyao, M. Ozeki, Y. Ikada, *J. Biomater. Sci., Polym. Ed.* **2000**, 11, 915; b) G. Sun, Y. I. Shen, S. Kusuma, K. Fox-Talbot, C. J. Steenbergen, S. Gerecht, *Biomaterials* **2011**, 32, 95.
- [14] M. D. Hoffman, A. H. Van Hove, D. S. Benoit, *Acta Biomater.* **2014**, 10, 3431.
- [15] S. Franz, S. Rammelt, D. Scharnweber, J. C. Simon, *Biomaterials* **2011**, 32, 6692.
- [16] Z. Xia, J. T. Triffitt, *Biomed. Mater.* **2006**, 1, R1.
- [17] a) A. Eirin, X. Y. Zhu, Z. L. Li, B. Ebrahimi, X. Zhang, H. Tang, M. J. Korsmo, A. R. Chade, J. P. Grande, C. J. Ward, R. D. Simari, A. Lerman, S. C. Textor, L. O. Lerman, *Arterioscler., Throm., Vasc. Biol.* **2013**, 33, 1006; b) S. M. Jay, B. R. Shepherd, J. W. Andrejcsk, T. R. Kyriakides, J. S. Pober, W. M. Saltzman, *Biomaterials* **2010**, 31, 3054.
- [18] a) B. E. Muhs, G. Plitas, Y. Delgado, I. Ianus, J. P. Shaw, M. A. Adelman, P. Lamparello, P. Shamamian, P. Gagne, *J. Surg. Res.* **2003**, 111, 8; b) W. Phatharajaree, A. Phrommintikul, N. Chattapakorn, *Can. J. Cardiol.* **2007**, 23, 727; c) D. T. Luttikhuisen, M. J. van Amerongen, P. C. de Feijter, A. H. Petersen, M. C. Harmsen, M. J. van Luyn, *Biomaterials* **2006**, 27, 5763.
- [19] B. E. Turk, L. L. Huang, E. T. Piro, L. C. Cantley, *Nat. Biotechnol.* **2001**, 19, 661.
- [20] H. K. Kleinman, G. R. Martin, *Semin. Cancer Biol.* **2005**, 15, 378.
- [21] a) A. B. Ennett, D. Kaigler, D. J. Mooney, *J. Biomed. Mater. Res., Part A* **2006**, 79A, 176; b) W. L. Murphy, M. C. Peters, D. H. Kohn, D. J. Mooney, *Biomaterials* **2000**, 21, 2521.
- [22] D. Seltikar, A. H. Zisch, M. P. Lutolf, J. L. Wrana, J. A. Hubbell, *J. Biomed. Mater. Res., Part A* **2004**, 68A, 704.
- [23] L. Pickart, *J. Biomater. Sci., Polym. Ed.* **2008**, 19, 969.
- [24] A. L. Akeson, C. W. Woods, L. C. Hsieh, R. A. Bohnke, B. L. Ackermann, K. Y. Chan, J. L. Robinson, S. D. Yanofsky, J. W. Jacobs, R. W. Barrett, T. L. Bowlin, *J. Biol. Chem.* **1996**, 271, 30517.
- [25] L. L. Yang, T. Mashima, S. Sato, M. Mochizuki, H. Sakamoto, T. Yamori, T. Oh-hara, T. Tsuruo, *Cancer Res.* **2003**, 63, 831.
- [26] X. Y. Chen, C. Plasencia, Y. P. Hou, N. Neamati, *J. Med. Chem.* **2005**, 48, 5874.
- [27] a) D. L. Hern, J. A. Hubbell, *J. Biomed. Mater. Res.* **1998**, 39, 266; b) C. N. Salinas, K. S. Anseth, *J. Tissue Eng. Regen. Med.* **2008**, 2, 296.
- [28] N. J. Anthis, G. M. Clore, *Protein Sci.* **2013**, 22, 851.
- [29] I. Arnaoutova, H. K. Kleinman, *Nat. Protoc.* **2010**, 5, 628.
- [30] A. Niemisto, V. Dunmire, O. Yli-Harja, W. Zhang, I. Shmulevich, *IEEE Trans. Med. Imaging* **2005**, 24, 549.
- [31] B. D. Fairbanks, M. P. Schwartz, A. E. Halevi, C. R. Nuttelman, C. N. Bowman, K. S. Anseth, *Adv. Mater.* **2009**, 21, 5005.
- [32] B. D. Fairbanks, M. P. Schwartz, C. N. Bowman, K. S. Anseth, *Biomaterials* **2009**, 30, 6702.
- [33] a) C. Napoli, A. Giordano, A. Casamassimi, F. Pentimalli, L. J. Ignarro, F. De Nigris, *Int. J. Cancer* **2011**, 128, 1505; b) L. Guede, A. M. Rivera, R. Salloum, M. L. Miller, J. J. Diegmüller, P. M. Bungay, W. G. Stetler-Stevenson, *Am. J. Pathol.* **2003**, 162, 1431.
- [34] M. Ehrbar, A. Metters, P. Zammaretti, J. A. Hubbell, A. H. Zisch, *J. Controlled Release* **2005**, 101, 93.
- [35] a) A. V. Belo, M. A. N. D. Ferreira, A. A. Bosco, R. D. P. Machado, S. P. Andrade, *Inflammation* **2001**, 25, 91; b) S. P. Andrade, R. D. P. Machado, A. S. Teixeira, A. V. Belo, A. M. Tarso, W. T. Beraldo, *Microvasc. Res.* **1997**, 54, 253; c) L. S. Barcelos, A. Talvani, A. S. Teixeira, G. D. Cassali, S. P. Andrade, M. M. Teixeira, *Inflammation Res.* **2004**, 53, 576.